Premium
Buprenorphine: 56‐day taper superior to 28 days in youth and young adults
Publication year - 2016
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30169
Subject(s) - buprenorphine , medicine , randomized controlled trial , psychological intervention , opioid , anesthesia , psychiatry , surgery , receptor
Buprenorphine is approved for the treatment of opioid use disorders for those 16 years and older, but few randomized controlled trials have been conducted evaluating interventions with youth. This study looked at two different taper lengths, and not at maintenance. The findings were clear: the longer taper (56 days) had much better results than the shorter one (28 days).